Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
PFTs
Do you implement FEV3/FEV6 or FEF25-75 measurements in the evaluation of patients for small airways obstruction?
Related Questions
How do you mitigate the risk of inadverdent under or over diagnosis of COPD in certain populations with transition to race-neutral spirometry reference equations?
What is your approach to addressing comorbidities that influence asthma severity?
Would you treat Scedosporium growth in expectorated sputum in a patient with COPD, pulmonary hypertension, and bronchiectasis, who has chronic dyspnea with exertion, thick sputum production, negative bacterial cultures, and no signs of mold infection on a high resolution CT scan, with no other clinical symptoms of infection?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Is there an upper threshold of pCO₂ that can cause symptomatic hypercapnia (e.g. AMS) despite metabolic compensation and normal pH?
How do you choose between dupilumab and mepolizumab for managing COPD in patients with eosinophilia?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
Would you stop Dupixent in an asthma patient who has good asthma control and notes improvement in loss of smell, but shows notable eosinophil elevation after 4-5 doses of the medication?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
